Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase

Canadian Journal of Cardiology

Volumn 15, Issue 2, 1999, Pages 173-179

  Massel, David ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Cost benefit analysis; Myocardial infarction; Neutralizing antibodies; Streptokinase; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ACETYLSALICYLIC ACID; PLASMINOGEN ACTIVATOR; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; COST EFFECTIVENESS ANALYSIS; HEART INFARCTION; HUMAN; MODEL; MORTALITY; SURVIVAL;

COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG RESISTANCE; ECONOMICS, PHARMACEUTICAL; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0033062726     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Cairns JA, Fuster V, Kennedy JW, Gore J, Kennedy JW. Coronary thromboLysis. Chest 1995;108(Suppl):401S-23S.
2. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-21.
3. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-5.
4. ISIS-3 Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70.
5. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
6. Califf RM, White HD, Van de Werf F, et al. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. Circulation 1996;94:1233-8.
7. Dalen JE, Gore JM, Braunwald E, et al. Six- and twelve-month follow-up of the Phase 1 Thrombolysis in Myocardial Infarction (TIMI) Trial. Am J Cardiol 1988;62:179-85.
8. Massel D. Canadian Consensus Conference on Thrombolytic Therapy. Previous SK therapy. Can J Cardiol 1993;9:518-20.
9. Canadian Consensus Conference on Coronary Thrombolysis - 1994 recommendations. Can J Cardiol 1994;10:522-9.
10. Goel V, Naylor CD. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction. Can J Cardiol 1992;8:31-8.
11. Naylor CD, Bronskill S, Goel V. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction. Can J Cardiol 1993;9:553-8.
12. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24.
13. Brieger DB, Mak K-H, White HD, et al. Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Am J Cardiol 1998;81:282-7.
14. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992;327:7-13.
15. Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Pauker SG. Cost-effectiveness of streptokinase for acute myocardial infarction. Med Decis Making 1994;14:108-17.
16. Fletcher AP, Alkjaersig N, Sherry S. The clearance of heterologous protein from the circulation of normal and immunized man. J Clin Invest 1958;37:1306-15.
17. Lynch M, Littler WA, Pentecost BL, Stockley RA. Antistreptokinase titres after intravenous streptokinase. Lancet 1990;335:534. (Lett)
18. Massel D, Turpie AGG, Cairns JA, Ofosu FA, Buchanan MR. Previous streptokinase therapy inhibits subsequent streptokinase thrombolysis. Circulation 1991;84(Suppl II):467. (Abst)
19. Buchalter MB. Are streptokinase antibodies clinically important? Br Heart J 1993;70:101-2. (Edit)
20. Lynch M, Littler WA, Pentecost BL, Stockley RA. Immunoglobulin response to intravenous streptokinase in acute myocardial infarction. Br Heart J 1991;66:139-42.
21. Massel D, Turpie AGO, Gill JB, et al. Development of neutralizing antibodies after 1.5 million units of streptokinase in the treatment of acute myocardial infarction. Circulation 1989;80(Suppl II):II350. (Abst)
22. Buchalter MB, Suntharalingam G, Jennings I, et al. Streptokinase resistance: when might streptokinase administration be ineffective? Br Heart J 1992;68:449-53.
23. Fears R, Ferres H, Glasgow E, et al. Monitoring of streptokinase resistance titres in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG. Br Heart J 1992;68:167-70.
24. Jalihal S, Morris GK. Antistreptokinase titres after intravenous streptokinase. Lancet 1990;335:184-5.
25. Fatel S, Jalihal S, Dutka DP, Morris GK. Streptokinase neutralisation titres up to 866 days after intravenous streptokinase for acute myocardial infarction. Br Heart J 1993;70:119-21.
26. Elliott JM, Cross DB, Cederholm-Williams SA, White HD. Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy. Am J Cardiol 1993;71:640-5.
27. AHA Medical/Scientific Statement. ACC/AHA Guidelines for the early management of patients with acute myocardial infarction. Circulation 1990:82:664-707.
28. Simoons ML, Vos J, Tijssen JG, et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted in the Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol 1989; 14:1609-15.
29. Baigent C, Collins R, Applehy P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 1998;316:1337-43.
30. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial infarction: The Framingham Study. Am J Cardiol 1979;44:53-9.
31. Metcalfe MJ, Rawles JM, Shirreffs C, Jennings K. Six year follow up of a consecutive series of patients presenting to the coronary care unit with acute chest pain: prognostic importance of the electrocardiogram. Br Heart J 1990;63:267-72.
32. Topol EJ. Thrombolytic intervention. In: Topol EJ, ed. Textbook of Interventional Cardiology, 2nd edn. Philadelphia: WB Saunders, 1994:68-111.
33. Naylor CD, Jaglal SB. Impact of intravenous thrombolysis on short-term coronary revascularizarion rates: A meta-analysis. JAMA 1990;264:697-702.
34. Van de Werf F, Topol EJ, Lee KL, et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO Trial. JAMA 1995;273:1586-91.
35. Rouleau JL, Moye LA, Pfeffer MA, et al. A comparison of management patterns after acute myocardial infarction in Canada and the United States. N Engl J Med 1993;328:779-84.
36. Pilote L, Granger C, Armstrong PW, Mark DB, Hlatky MA. Differences in the treatment of myocardial infarction between the United States and Canada. A survey of physicians in the GUSTO Trial. Med Care 1995;33:598-610.
37. Tu JV, Pashos CL, Naylor CD, et al. Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in the United States and Canada. N Engl J Med 1997;336:1500-5.